Celldex Therapeutics (CLDX) Long-Term Deferred Tax (2019 - 2020)
Celldex Therapeutics (CLDX) recorded quarterly Long-Term Deferred Tax of $297.3 million in Q4 2020, down 0.94% quarter-over-quarter from $300.2 million in Q4 2019, and down 0.94% on a YoY basis from $300.2 million in Q1 2020.
Celldex Therapeutics (CLDX) Long-Term Deferred Tax (2019 - 2020) Analysis & Trends
Celldex Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $297.3 million for Q4 2020.
- In Q4 2020, Long-Term Deferred Tax fell 0.94% year-over-year to $297.3 million; the TTM figure through Dec 2020 stood at $297.3 million (down 0.94% YoY), while the FY2020 annual figure was $297.3 million, down 0.94% from the prior year.
- Long-Term Deferred Tax was $297.3 million for Q4 2020 at Celldex Therapeutics, down from $300.2 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $300.2 million in Q4 2019 to a low of $297.3 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Celldex Therapeutics | 2.16 Bn | 2.16 Bn | -1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 297.34 Mn |
| Dec 31, 2019 | 300.17 Mn |